Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025 -1.11% 2.225 2.20 2.25 2.25 1.975 2.25 32,793,766 16:25:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.1 -0.0 - 72

Sareum Share Discussion Threads

Showing 12451 to 12472 of 12575 messages
Chat Pages: 503  502  501  500  499  498  497  496  495  494  493  492  Older
DateSubjectAuthorDiscuss
26/3/2021
22:58
If he's partially right in his/hers forecasts that will do me, it's a Friday night and I am now mellowed and very happy with the latest movements, like my view matters.So let's all be happy things hopefully are on the way up20 to 30p forecasts if they came true would-be fantastic life changing prices for me,hopefully more but we shall see.
silvergreyhead1
25/3/2021
19:32
When is this presentation
spacedust
25/3/2021
14:29
The last sentence. Thats a 163 billion market. A 1% market share would see us at 20 pounds. Somewhere in between now and then see me happy
mrsapeslaptop
25/3/2021
14:21
Interesting, very interesting
kris akabusi
25/3/2021
14:20
Any comments on the second RNS
ohsod1t
25/3/2021
12:56
Half yearly is unaudited so forget blaming busy accountants. Last year they announced a the Aurora deal on same day, post period highlights is the big one, and they need to deliver. Program updates always included, pushed back to allow for this. IMO
monstersound
25/3/2021
09:19
Sorry Monster rereading it does seem tetchy no offence meant just giddy after last week's share price drops. Quite right of Barkboo we are all on the same side unless we live in the dark half
silvergreyhead1
25/3/2021
09:08
ASCO 14April. hxxps://www.abstractsonline.com/pp8/#!/9325/presentation/2082 Im expecting an onlicence to astrazeneca. not just for Wee1 (which Ive been waiting for for years to be honest, but also as a PD-1 combo with olaparib (based to Triparna Sen research last year. Olaparib needs a combo to take on keytruda, and if we can piggyback on $3bn pa sales currently not complaining. all IMHO and a bit wishfull but been waiting years for this tie up. (oh and Olaparib also came out of ICR, so the odds they havent looked at this combo is zero).
mrsapeslaptop
25/3/2021
09:07
CQ - your first paragraph highlights the very point I was making...the accounts would not be delayed because of auditors/lockdown...this has not been a problem with other companies. Sar have delayed to include an important announcement imo. - money always talks!
barkboo
25/3/2021
09:06
Apart from the earnings what other announcements would we expect.
red5
25/3/2021
08:59
Silver - you are of a touchy nature...we are on the same side my friend.
barkboo
25/3/2021
08:40
So what good news does a connected person like you know then?
silvergreyhead1
25/3/2021
08:24
A strange rns - a strange price reaction? The telling point was in yesterday's sudden, and very fast price movement - no news, plenty of money lumped on. In this game - there is no hiding place when the money goes on...the rns'd extension was used to include news imo....one can only imagine the news is good.
barkboo
25/3/2021
08:22
My sentiments exactly. Blaming the Chinese Visitor is a fabricated excuse imo.
husbod
25/3/2021
08:16
This is a huge Buy signal. The leaks are coming, delay of results is stupid and the good news will now be leaked to those of us who hold the connections. Fill your boots while you can.
monstersound
25/3/2021
08:11
Strange share price reaction to an announcement of a delay in results.
husbod
25/3/2021
07:55
My reading is that SAR have done themselves no favours taking the one month extension route. They have no accounting issues ie very few receivables and payables. I assume the reason is delay in being able to submit the CTA and for me it would be better to be clear about this.
cerrito
25/3/2021
05:48
3 reasons. 1. Aacr presentation. Hosted by astra who own the wee1. Note olaparib is also astra and the class of pd-1 inhibitors that sra 737 synergises with according to t sen last year. 2. Tyk2. Treatments for c 19 not a 2 year deal but permanent. 3. Dexamethasone. Leading treatment. Already trialled as a combo in 2017. Not in c19 but no adveree efficacy. All good
mrsapeslaptop
24/3/2021
17:39
Could this be the reason for the raise. Interesting presentation coming up in April, this could be the news we are waiting. hxxps://www.abstractsonline.com/pp8/#!/9325/presentation/2082
curriedquaker
24/3/2021
14:29
Mms got bored
spacedust
24/3/2021
14:22
Any idea why the rise?
herb clark
24/3/2021
14:22
Worried investors - not so worried now.
barkboo
Chat Pages: 503  502  501  500  499  498  497  496  495  494  493  492  Older
ADVFN Advertorial
Your Recent History
LSE
SAR
Sareum
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210505 22:46:06